An interventional study of Financial Navigation in Neoplasms and Carcinoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by UNC Lineberger Comprehensive Cancer Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 403 studies in Carcinoma with a site in United States — 71 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.
Among the 403 studies in Carcinoma with a site in United States, this one is the 68th largest by enrollment of the 359 interventional ones that give a count, is one of 17 that started in 2021, is one of 22 with no phase, and was the 305th registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →71 of the 403 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120 · Men only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Pfizer · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
403 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 162 · Phase 2 171 · Phase 3 53 · Phase 4 7
First in 1996; this study’s year is marked. 17 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 205 is above the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 48 across the 359 interventional studies, 108 across the 40 observational. Of the 268 that completed or were terminated, 121 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
211 of 403 have an industry lead sponsor. The 10 most frequent:
UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 431 studies on the registry; 96 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
UNC Lineberger Comprehensive Cancer Center has 2 studies filed under Carcinoma — fewer than ten, so there is no comparison to draw.
32 of the studies in Carcinoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT04520711Providence Health & ServicesHotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | 2026-12 |
| NCT05768932SillaJen, Inc.BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | 2026-12-24 |
| NCT05283226NATCO Pharma Ltd.Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | 2026-12-30 |
| NCT02659241M.D. Anderson Cancer CenterAdavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | 2026-12-31 |
Add all 32 to your calendar (.ics) → With an account.
Among the 403 studies in Carcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The financial burden, or financial toxicity (FT), of cancer is a consequential and growing problem, particularly for rural patients. It is important to improve our understanding of how financial navigation (FN) can reduce the material, psychological, and behavioral burden of costs associated with cancer care in both rural and non-rural community settings. The purpose of this study is to conduct a financial navigation program in 4 rural and 4 non-rural oncology practices in North Carolina and evaluate the effects of financial navigation on patient outcomes, including financial toxicity and health-related quality of life.
The objective of this study was to evaluate changes in financial toxicity, as measured by the COmprehensive Score for financial Toxicity (FACIT-COST) from baseline to follow-up after participation in a financial navigation program among rural and non-rural cancer patients in North Carolina with moderate to severe financial toxicity.
After providing informed consent, participants completed the FACIT-COST measure (score range: 0-44, with lower scores indicating greater financial toxicity). Participants with a score of 22 or lower, indicating moderate to severe financial toxicity, were eligible to enroll in the financial navigation intervention. Those with scores of 23 or higher were not eligible.
This implementation study was conducted across eight oncology practices in North Carolina (four rural and four non-rural). Eligible participants completed baseline questionnaires assessing health-related quality of life before meeting with a financial navigator for a comprehensive assessment of financial needs and identification of available financial assistance resources. Participants continued to work with the financial navigator until all appropriate assistance options had been explored and applications, benefits, or referrals were completed.
At the conclusion of the intervention, participants repeated the FACIT-COST measure and baseline questionnaires to assess changes in financial toxicity, health-related quality of life, and the acceptability of the financial navigation program. The intervention typically involved two to six visits with a financial navigator over approximately four months, although participation could extend longer depending on the complexity of the participant's financial needs.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
This study's enrollment of 205 is above the median of 49 across 571 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 431 studies on the registry; 96 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
Compared within Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
includes a financial toxicity screening measure (COST), baseline and post-intervention surveys, and approximately 2-6 visits with a financial navigator to identify financial assistance resources
Behavioral: Financial Navigation
providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
COST (Comprehensive Score for Financial Toxicity) Measure
To evaluate changes in financial toxicity from baseline to follow-up, participants completed the 12-item Functional Assessment of Chronic Illness Therapy-Comprehensive Score for Financial Toxicity (FACIT-COST) before and after the financial navigation intervention. FACIT-COST scores range from 0 to 44, with higher scores indicating lower financial toxicity (less financial distress) and lower scores indicating greater financial toxicity (more financial distress). Therefore, an increase in score reflects improvement, whereas a decrease reflects worsening financial toxicity.
Time frame: 4-6 months
Health-Related Quality of Life (HrQoL) Measures
To evaluate changes in health-related quality of life (HRQoL) from baseline to follow-up, participants completed the Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Physical Health, Global Mental Health, Anxiety 6a, Depression 4a, and Psychosocial Illness Impact-Positive instruments. PROMIS T-scores are standardized with a mean of 50 (SD = 10). For Global Physical Health, Global Mental Health, and Psychosocial Illness Impact-Positive, higher scores indicate better health or more positive psychosocial functioning. For Anxiety and Depression, higher scores indicate greater symptom severity; therefore, decreases in these scores reflect improvement, whereas increases reflect worsening symptoms.
Time frame: 4-6 months
At each of the 8 participating oncology practices, uninsured cancer patients and patients expressing financial concerns on existing distress screening measures or through communication with clinic staff were approached by the financial navigator to participate in this study
| Milestone | Financial Navigation |
|---|---|
| Started | 205 |
| Completed | 179 |
| Not completed | 26 |
| Withdrew: Lost to follow-up | 17 |
| Withdrew: Death | 5 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Multiple reasons | 3 |
To evaluate changes in financial toxicity from baseline to follow-up, participants completed the 12-item Functional Assessment of Chronic Illness Therapy-Comprehensive Score for Financial Toxicity (FACIT-COST) before and after the financial navigation intervention. FACIT-COST scores range from 0 to 44, with higher scores indicating lower financial toxicity (less financial distress) and lower scores indicating greater financial toxicity (more financial distress). Therefore, an increase in score reflects improvement, whereas a decrease reflects worsening financial toxicity.
| score on a scale | Baseline Financial Navigation | Follow-up Financial Navigation |
|---|---|---|
| COST (Comprehensive Score for Financial Toxicity) Measure | 6.6 ± 5.1 | 14.7 ± 10.2 |
To evaluate changes in health-related quality of life (HRQoL) from baseline to follow-up, participants completed the Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Physical Health, Global Mental Health, Anxiety 6a, Depression 4a, and Psychosocial Illness Impact-Positive instruments. PROMIS T-scores are standardized with a mean of 50 (SD = 10). For Global Physical Health, Global Mental Health, and Psychosocial Illness Impact-Positive, higher scores indicate better health or more positive psychosocial functioning. For Anxiety and Depression, higher scores indicate greater symptom severity; therefore, decreases in these scores reflect improvement, whereas increases reflect worsening symptoms.
| score on a scale | Baseline Health-Related Quality of Life (HRQoL) | Follow-up Health-Related Quality of Life (HRQoL) |
|---|---|---|
| Global Mental Health | 29.76 ± 7.61 | 41.49 ± 7.83 |
| Anxiety | 62.43 ± 8.58 | 59.10 ± 9.37 |
| Depression | 57.05 ± 9.60 | 54.98 ± 9.67 |
Collected over median: 4.5 months; interquartile range (IQR) : 3 - 8 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Financial Navigation | 5/205 (2.4%) | 0/205 (0%) | 0/205 (0%) |
Participants began the financial navigation intervention.
| Age, Continuous(years) | Financial Navigation |
|---|---|
| Mean | 53.2 (22 to 81) |
| Sex/Gender, Customized(Participants) | Financial Navigation |
|---|---|
| Female | 132 |
| Male | 70 |
| Unknown | 3 |
| Ethnicity (NIH/OMB)(Participants) | Financial Navigation |
|---|---|
| Hispanic or Latino | 15 |
| Not Hispanic or Latino | 190 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Financial Navigation |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 72 |
| White | 116 |
| More than one race | 3 |
| Unknown or Not Reported | 12 |
| Region of Enrollment(Participants) | Financial Navigation |
|---|---|
| United States | 205 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified data are available upon reasonable request by contacting the study authors and signing the study Data Use Agreement.
Supporting information: Study protocol
Ran from Nov 2021 to primary completion in Jul 2025, 44 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 29 interventional studies with no phase under Carcinoma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 44 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UNC Lineberger Comprehensive Cancer Center →